Home / Companies / Mersana Therapeutics, Inc. / 11 Jun 2024
Mersana Therapeutics, Inc.: meeting of 11 Jun 2024
Votes reported on Form N-PX, item by item
193 Form N-PX filers reported votes at the Mersana Therapeutics, Inc. meeting of 11 Jun 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
2 nominees; 78.0% of reported votes for; 34 filers withheld from or voted against at least one nominee.
244 vote records from 68 filers. 1 of the 68 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
278 vote records from 193 filers. 16 of the 188 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
122 vote records from 68 filers. 0 of the 68 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | No report | For | No report |
| State Street and SPDR | For | For | For |
| Invesco | Split or no vote | Against * | For |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Split or no vote | For | For |
| John Hancock and Manulife | Split or no vote | For | For |
| Morgan Stanley, Eaton Vance and Calvert | For | Against * | For |
| J.P. Morgan | For | For | For |
| Goldman Sachs | No report | For | No report |
| PGIM and Prudential | No report | For | No report |
| Jackson National funds | Against * | For | For |
| Northern Trust and FlexShares | No report | For | No report |
| SEI | For | For | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | For | For | For |
| Voya | Split or no vote | For | For |
| Nationwide | For | For | For |
| Victory Capital | Split or no vote | For | For |
| Brighthouse Funds | Split or no vote | For | For |
| Guggenheim and Rydex | Split or no vote | For | For |
| Columbia Threadneedle | No report | For | No report |
| BNY Mellon | No report | For | No report |
| Principal | For | For | For |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| AllianceBernstein | No report | For | No report |
| DWS | Split or no vote | For | For |
| Macquarie and Delaware Funds | Split or no vote | For | For |
| Janus Henderson | No report | For | No report |
| Neuberger Berman | No report | For | No report |
| Natixis and Loomis Sayles | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Mersana Therapeutics, Inc. meeting?
193 Form N-PX filers reported votes at the meeting of 11 Jun 2024. On say-on-pay, 16 of 188 voted against management (8.5%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Mersana Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Mersana Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Mersana Therapeutics, Inc. with a meeting date within three days of 11 Jun 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.